1 min read
Add as a preferred source on GoogleMcKesson Is Closing a $2.25 Billion Precision Medicine Group Deal
The deal comes as McKesson’s fiscal 2027 adjusted earnings outlook stands at $45.60 to $46.40 per diluted share.
McKesson Corporation is closing a deal valued at about $2.25 billion for Precision Medicine Group.
McKesson’s fiscal 2027 adjusted earnings per diluted share outlook stands at $45.60 to $46.40, up from $44.20 to $45.00 after second-quarter results.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.